前立腺がん診断の世界市場レポート 2024

前立腺がん診断の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には12.7%の年間複合成長率（CAGR）で71億1,000万米ドルに成長すると予想されます。予測期間で予想される成長は、人工知能（AI）の統合、がんスクリーニングにおける遠隔医療の成長、ゲノムプロファイリングの進歩、患者中心のアプローチ、診断におけるマルチパラメータMRIの利用に起因すると考えられます。予測期間中に予想される主な動向には、リキッドバイオプシー技術の採用、バイオマーカー検出の技術進歩、臨床研究開発への注目の高まり、デジタルパソロジーの統合、マルチプレックスバイオマーカーアッセイの出現などが含まれます。

前立腺がん診断市場は、前立腺がんの罹患率の増加により成長が見込まれています。この症状は、男性および女性の生殖器系の前立腺に影響を与えるため、前立腺特異抗原（PSA）検査や高度な画像技術などのさまざまな検査による早期診断が必要です。 2023年1月、米国がん協会（ACS）は、同年の推定28万8,300人の新たな前立腺がん症例と、この疾患による死亡者数3万4,700人を報告しました。その結果、前立腺がんの有病率の上昇が前立腺がん診断市場の拡大を促進すると予想されます。

前立腺がん診断市場の成長は、ヘルスケア支出の増加によってさらに促進されています。ヘルスケア支出は、ヘルスケア部門に割り当てられた総財源を反映しており、前立腺がん診断へのリソース割り当てを促進します。この割り当ては、早期発見、正確な病期分類、タイムリーな介入をサポートし、患者の転帰、生存率、全体的なケアの質の向上を目指します。米国医師会（AMA）によると、2021年の米国の医療支出は2.7％増加し、4兆3,000億米ドル（1人当たり1万2,914米ドル）に達しました。したがって、ヘルスケア支出の増加傾向は前立腺がん診断市場の成長に貢献します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の前立腺がん診断市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 機器
• 試薬と消耗品
• アクセサリー
• 世界の前立腺がん診断市場、検査タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 予備検査
• 確認検査
• 世界の前立腺がん診断市場、前立腺がん別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 扁平上皮がん
• 小細胞がん
• 移行上皮がん
• 前立腺腺がん
• 乳管腺がん
• 小細胞前立腺がん
• 腺房腺がん
• 世界の前立腺がん診断市場、年齢グループ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 成人
• 小児
• 老人
• 世界の前立腺がん診断市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 独立した診断研究所
• がん研究
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の前立腺がん診断市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の前立腺がん診断市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺がん診断市場の競合情勢
• 前立腺がん診断市場の企業プロファイル
  • F. Hoffman-La Roche AG
  • Bayer AG
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories Inc.
  • Siemens Healthineers AG

第31章 その他の大手および革新的な企業

• Becton Dickinson and Company
• Agilent Technologies Inc.
• Hologic Inc
• Biomerieux SA
• Beckman Coulter Inc.
• Qiagen NV
• EXACT Sciences Corporation
• Diasorin SPA
• OPKO Health Inc.
• Myriad Genetics Inc.
• Cepheid Inc
• NeoGenomics Laboratories Inc.
• Guardant Health Inc
• GRAIL Inc
• Fujirebio Diagnostics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Prostate cancer diagnostics involve the process of determining and confirming the presence of prostate cancer through diagnostic testing and medical evaluations. The primary aim is to assess the status and severity of the illness, guiding treatment choices. This diagnostic approach is commonly applied in the treatment of prostatic adenocarcinoma, transitional cell carcinomas, and neuroendocrine tumors.

The main products in prostate cancer diagnostics include instruments, reagents and consumables, and accessories. Accessories encompass items in the kit that may not be strictly necessary but can enhance effectiveness, such as a prostate-specific antigen (PSA) test kit, biopsy needle, and ultrasound gel, all utilized in the diagnosis of prostate cancer. Various test types, including preliminary and confirmatory tests, diagnose different types of prostate cancers, such as squamous cell cancer, small cell carcinoma, transitional cell cancer, prostatic adenocarcinoma, ductal adenocarcinoma, small cell prostate cancer, and acinar adenocarcinoma. These diagnostic tests are applicable to various age groups, including adults, pediatric, and geriatric populations, and are performed by different end users, including hospitals, independent diagnostic laboratories, cancer research institutes, and others.

The prostate cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer diagnostics market statistics, including prostate cancer diagnostics industry global market size, regional shares, competitors with a prostate cancer diagnostics market share, detailed prostate cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer diagnostics industry. This prostate cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer diagnostics market size has grown rapidly in recent years. It will grow from $3.86 billion in 2023 to $4.4 billion in 2024 at a compound annual growth rate (CAGR) of 14.1%. The expansion observed in the historical period can be attributed to factors such as the increasing aging population, advancements in medical imaging technologies, rising awareness and screening programs, public health initiatives, and improvements in biopsy techniques.

The prostate cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $7.11 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth in the forecast period can be attributed to the integration of artificial intelligence (AI), the growth of telemedicine in cancer screening, advancements in genomic profiling, patient-centric approaches, and the utilization of multiparametric MRI for diagnosis. Key trends expected in the forecast period include the adoption of liquid biopsy technologies, technological advances in biomarker detection, increased focus on clinical research and development, integration of digital pathology, and the emergence of multiplex biomarker assays.

The prostate cancer diagnostics market is anticipated to experience growth, driven by the increasing prevalence of prostate cancer. This condition, affecting the prostate gland in the male and female reproductive systems, necessitates early diagnosis through various tests, including prostate-specific antigen (PSA) testing and advanced imaging techniques. In January 2023, the American Cancer Society (ACS) reported an estimated 288,300 new cases of prostate cancer and 34,700 deaths attributed to the disease for the same year. Consequently, the rising prevalence of prostate cancer is expected to fuel the expansion of the prostate cancer diagnostics market.

The growth of the prostate cancer diagnosis market is further propelled by an increase in healthcare spending. Healthcare spending, reflecting the total financial resources allocated to the healthcare sector, facilitates resource allocation for prostate cancer diagnosis. This allocation supports early detection, accurate staging, and timely intervention, aiming to enhance patient outcomes, survival rates, and overall quality of care. According to the American Medical Association (AMA), health spending in the United States increased by 2.7% in 2021, reaching $4.3 trillion or $12,914 per capita. Therefore, the upward trend in healthcare spending contributes to the growth of the prostate cancer diagnosis market.

Technological innovations represent a prominent trend in the prostate cancer diagnostics market, with major companies introducing advanced AI-powered tools for diagnosis. In March 2023, Qritive, a Singapore-based company, launched QAi Prostate-an AI-powered prostate cancer diagnosis tool designed for pathologists. This tool employs sophisticated machine learning algorithms to identify prostatic adenocarcinoma regions and analyze whole slide images of prostate core needle biopsies. The innovative tool facilitates accurate and swift diagnoses, reducing treatment time.

Strategic partnerships are a key approach adopted by major companies in the prostate cancer diagnostics market to advance cancer precision medicine. In March 2022, Lantheus Holdings Inc., a US-based diagnostic and imaging products company, partnered with Novartis AG, a Switzerland-based pharmaceutical company, to utilize Lantheus' prostate-specific membrane antigen (PSMA) imaging agent, PYLARIFY, in clinical trials for Pluvicto. This collaboration aims to enhance the diagnosis of patients with prostate cancer for improved treatment outcomes.

In August 2022, MDxHealth SA, a US-based precision diagnostics company, acquired Exact Sciences Corporation to bolster its leadership in the precision diagnostics urology market. This acquisition expanded MDxHealth's prostate diagnostics business with the inclusion of the Oncotype DX GPS (Genomic Prostate Score) test. Exact Sciences Corporation, a US-based cancer screening and diagnostic tests company, brought valuable assets, including prostate pipelines software supporting patients throughout their cancer diagnosis and treatment.

Major companies operating in the prostate cancer diagnostics market report are F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Siemens Healthineers AG, Becton Dickinson and Company, Agilent Technologies Inc., Hologic Inc., Biomerieux SA, Beckman Coulter Inc., Qiagen N.V., EXACT Sciences Corporation, Diasorin S.P.A., OPKO Health Inc., Myriad Genetics Inc., Cepheid Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., GRAIL Inc., Fujirebio Diagnostics Inc., Ambry Genetics Corporation, MDxHealth SA, Biocept Inc., Blue Earth Therapeutics Ltd., Exosome Diagnostics Inc., Eurolyser Diagnostica GmbH, Dana-Farber Cancer Institute, Vyant Bio Inc., Cellanyx Diagnostics Inc., A3P Biomedical AB

North America was the largest region in the prostate cancer diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prostate cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer diagnostics market consists of revenues earned by entities by providing transrectal ultrasound, magnetic resonance imaging (MRI), and computerized tomography (CT) scans. The market value includes the value of related goods sold by the service provider or included within the service offering. The prostate cancer diagnostics market also includes sales of products such as tumor biopsies, and test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Diagnostics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Products: Instruments; Reagents And Consumables; Accessories
• 2) By Test Type: Preliminary Tests; Confirmatory Tests
• 3) By Prostate Cancer: Squamous Cell Cancer; Small Cell Carcinoma; Transitional Cell Cancer; Prostatic Adenocarcinoma; Ductal Adenocarcinoma; Small Cell Prostate Cancer; Acinar Adenocarcinoma
• 4) By Peer Groups: Adult; Pediatric; Geriatrics
• 5) By End User: Hospitals; Independent Diagnostic Laboratories; Cancer Research Institutes; Other End-Users
• Companies Mentioned: F. Hoffman-La Roche AG; Bayer AG; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Siemens Healthineers AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Prostate Cancer Diagnostics Market Characteristics

3. Prostate Cancer Diagnostics Market Trends And Strategies

4. Prostate Cancer Diagnostics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Prostate Cancer Diagnostics Market Size and Growth

• 5.1. Global Prostate Cancer Diagnostics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Prostate Cancer Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Prostate Cancer Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Prostate Cancer Diagnostics Market Segmentation

• 6.1. Global Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Instruments
• Reagents And Consumables
• Accessories
• 6.2. Global Prostate Cancer Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Preliminary Tests
• Confirmatory Tests
• 6.3. Global Prostate Cancer Diagnostics Market, Segmentation By Prostate Cancer, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Squamous Cell Cancer
• Small Cell Carcinoma
• Transitional Cell Cancer
• Prostatic Adenocarcinoma
• Ductal Adenocarcinoma
• Small Cell Prostate Cancer
• Acinar Adenocarcinoma
• 6.4. Global Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Adult
• Pediatric
• Geriatrics
• 6.5. Global Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Independent Diagnostic Laboratories
• Cancer Research Institutes
• Other End-Users

7. Prostate Cancer Diagnostics Market Regional And Country Analysis

• 7.1. Global Prostate Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Prostate Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Prostate Cancer Diagnostics Market

• 8.1. Asia-Pacific Prostate Cancer Diagnostics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Prostate Cancer Diagnostics Market

• 9.1. China Prostate Cancer Diagnostics Market Overview
• 9.2. China Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Prostate Cancer Diagnostics Market

• 10.1. India Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Prostate Cancer Diagnostics Market

• 11.1. Japan Prostate Cancer Diagnostics Market Overview
• 11.2. Japan Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Prostate Cancer Diagnostics Market

• 12.1. Australia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Prostate Cancer Diagnostics Market

• 13.1. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Prostate Cancer Diagnostics Market

• 14.1. South Korea Prostate Cancer Diagnostics Market Overview
• 14.2. South Korea Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Prostate Cancer Diagnostics Market

• 15.1. Western Europe Prostate Cancer Diagnostics Market Overview
• 15.2. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Prostate Cancer Diagnostics Market

• 16.1. UK Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Prostate Cancer Diagnostics Market

• 17.1. Germany Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Prostate Cancer Diagnostics Market

• 18.1. France Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Prostate Cancer Diagnostics Market

• 19.1. Italy Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Prostate Cancer Diagnostics Market

• 20.1. Spain Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Prostate Cancer Diagnostics Market

• 21.1. Eastern Europe Prostate Cancer Diagnostics Market Overview
• 21.2. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Prostate Cancer Diagnostics Market

• 22.1. Russia Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Prostate Cancer Diagnostics Market

• 23.1. North America Prostate Cancer Diagnostics Market Overview
• 23.2. North America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Prostate Cancer Diagnostics Market

• 24.1. USA Prostate Cancer Diagnostics Market Overview
• 24.2. USA Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Prostate Cancer Diagnostics Market

• 25.1. Canada Prostate Cancer Diagnostics Market Overview
• 25.2. Canada Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Prostate Cancer Diagnostics Market

• 26.1. South America Prostate Cancer Diagnostics Market Overview
• 26.2. South America Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Prostate Cancer Diagnostics Market

• 27.1. Brazil Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Prostate Cancer Diagnostics Market

• 28.1. Middle East Prostate Cancer Diagnostics Market Overview
• 28.2. Middle East Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Prostate Cancer Diagnostics Market

• 29.1. Africa Prostate Cancer Diagnostics Market Overview
• 29.2. Africa Prostate Cancer Diagnostics Market, Segmentation By Products, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Prostate Cancer Diagnostics Market, Segmentation By Peer Groups, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Prostate Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Prostate Cancer Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Prostate Cancer Diagnostics Market Competitive Landscape
• 30.2. Prostate Cancer Diagnostics Market Company Profiles
  • 30.2.1. F. Hoffman-La Roche AG
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bayer AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Thermo Fisher Scientific Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Abbott Laboratories Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Siemens Healthineers AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Prostate Cancer Diagnostics Market Other Major And Innovative Companies

• 31.1. Becton Dickinson and Company
• 31.2. Agilent Technologies Inc.
• 31.3. Hologic Inc
• 31.4. Biomerieux SA
• 31.5. Beckman Coulter Inc.
• 31.6. Qiagen N.V.
• 31.7. EXACT Sciences Corporation
• 31.8. Diasorin S.P.A.
• 31.9. OPKO Health Inc.
• 31.10. Myriad Genetics Inc.
• 31.11. Cepheid Inc
• 31.12. NeoGenomics Laboratories Inc.
• 31.13. Guardant Health Inc
• 31.14. GRAIL Inc
• 31.15. Fujirebio Diagnostics Inc.

32. Global Prostate Cancer Diagnostics Market Competitive Benchmarking

33. Global Prostate Cancer Diagnostics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Prostate Cancer Diagnostics Market

35. Prostate Cancer Diagnostics Market Future Outlook and Potential Analysis

• 35.1 Prostate Cancer Diagnostics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Prostate Cancer Diagnostics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Prostate Cancer Diagnostics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer